Accueil   Diary - News   All news Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH

Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH

 

 

  • The Phase 2a program will include two separate studies
  • Phase 2a efficacy and safety study for PXL770 is underway with data results anticipated 1H 2020
  • Pharmacokinetic (PK)/pharmacodynamic (PD) study for PXL770 is expected to initiate 2Q 2019 with results anticipated 2H 2019

 

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced initiation of the Phase 2a program for PXL770, a direct adenosine monophosphate-activated protein kinase activator (AMPK), for the treatment of NASH.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree